Enanta sets up $75 million at-the-market stock sale program with Jefferies
Enanta Pharmaceuticals entered a sales agreement allowing it to sell up to $75 million of common stock over time through Jefferies LLC.
Enanta Pharmaceuticals, Inc. disclosed in an 8-K filing that on July 2, 2026, it entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, allowing the company to offer and sell shares of its common stock from time to time through the agent.1
The offering is made under an existing shelf registration. The stock is being offered and sold under Enanta's previously filed and currently effective shelf registration statement on Form S-3, filed with the SEC on February 11, 2026 and declared effective on February 20, 2026, under Registration Statement No. 333-293390.1 The company filed a related prospectus supplement dated July 2, 2026.1 Under that supplement, Enanta may offer and sell shares with an aggregate offering price of up to $75,000,000.1
Sales under the program will be structured as an at-the-market offering. Sales through the agent, if any, will be made by any method permitted by law considered an "at the market offering" under Rule 415(a)(4), including direct sales on the Nasdaq Global Select Market or other existing trading markets for the common stock.1 Jefferies will use commercially reasonable efforts to sell the stock based on Enanta's instructions, including any price, time, or size parameters, but the company has no obligation to sell any shares under the agreement.1
On compensation, Enanta will pay Jefferies a commission of up to 3.0% of the gross sales price per share sold under the agreement.1 The company also provided customary indemnification rights to the agent.1 The offering will terminate upon termination of the sales agreement according to its terms.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.